EarningsQ2 2026 Earnings Report
MX:CVS Q2 2026 EPS Results
Actual EPS$43.63
Consensus EPS$31.36
Beat/MissBeat by +$12.28
One Year Ago EPS$30.61
MX:CVS Q2 2026 Revenue Results
Actual Revenue$1.79T
Expected Revenue$1.69T
Beat/MissBeat by +$102.84B
YoY Revenue Growth+7.24%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
MX:CVS Upcoming Earnings
CVS Health's next earnings date is estimated for November 4, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:CVS Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum across segments with material upside: double-digit growth in operating income, raised EPS guidance, improved cash flow outlook, specialty leadership, and early tangible AI-driven efficiencies. Offsetting these positives are notable industry-specific headwinds—most prominently near-term 340B pressures, anticipated Caremark membership declines in 2027, ongoing reimbursement and regulatory pressures, and some timing-related pull-forwards. Management emphasized disciplined execution, balance sheet improvement and a multi-year growth outlook (mid-teens EPS CAGR through 2028), while acknowledging and preparing for specific near-term headwinds.Company Guidance
Strong top-line performance
Total revenue exceeded $106 billion in Q2 2026, an increase of over 7% year-over-year, with full year 2026 total revenues now expected to be at least $414 billion.
Significant operating income and EPS growth
Adjusted operating income for the quarter was $5.2 billion (up ~35% year-over-year) and adjusted EPS was $2.58 (up over 40% year-over-year). Enterprise adjusted operating income guidance for 2026 is now $16.58 billion to $16.92 billion.
Guidance raised and cash flow improvement
Full year 2026 adjusted EPS guidance was raised by $0.60 to $7.90–$8.10 (about +8% versus prior guidance). Full year cash flow from operations outlook increased to at least $11.5 billion, a $2.0 billion raise from prior guidance; YTD cash flow from operations was ~$10.6 billion.
Health Care Benefits (Aetna) margin recovery
Health Care Benefits revenue was over $37 billion in the quarter (up >3% YoY). Adjusted operating income was approximately $2.4 billion and the medical benefit ratio improved to 87.4%. Management delivered more than $2 billion of year-over-year improvement in adjusted operating income so far this year.
Health Services (Caremark) growth
Health Services revenue was nearly $52 billion (up >11% YoY) with adjusted operating income over $1.7 billion (up ~10% YoY), driven by improved purchasing economics, favorable pharmacy drug mix and specialty performance.
Pharmacy & Consumer Wellness momentum
PCW revenues were nearly $34 billion (slight increase YoY). Adjusted operating income nearly $1.5 billion (up >10% YoY). Same-store pharmacy sales grew ~3%, same-store prescription volumes rose ~7%, and front-store sales improved ~100 basis points. Rite Aid transaction contributed to volume gains.
Specialty pharmacy leadership and adherence
CVS Specialty maintains industry-leading tech-enabled operations with adherence rates consistently above 90% (versus ~80% industry standard), supporting faster therapy initiation and better outcomes.
Technology and AI investments and early benefits
Company reaffirmed $20+ billion technology investment commitment over the next decade, launched Health100 and Haio AI assistant (targeted rollout underway). AI-enabled claims assist manager expected to cut processing time by over 20% and accelerate payments on hundreds of millions of claims. Management reports >$1 billion of OpEx savings realized from technology and AI initiatives to date.
Balance sheet and capital return discipline
Leverage ratio at quarter end ~3.5x with parent/unrestricted cash of ~$2.7 billion. Company returned over $1.7 billion to shareholders via dividends YTD and is prudently managing capital deployment (no share repurchases assumed in current 2026 outlook).
Constructive early outlook for 2027
Management provided preliminary 2027 commentary and indicated an EPS floor of at least $8.44 (roughly +13% growth off an adjusted baseline of $7.46) and reiterated confidence in mid-teens adjusted EPS CAGR for 2025–2028.
MX:CVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed